Effects of long‐term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine whether the phosphodiesterase‐5 (PDE5) inhibitor, vardenafil, given orally and in different regimens, has a similar effect to that of the PDE5 inhibitor sildenafil, which prevented the development of a Peyronie's disease (PD)‐like plaque formation induced by injecting transforming growth factor β1 (TGF‐β1) into the tunica albuginea of the rat. MATERIALS AND METHODS: Vardenafil was given to male rats (eight per group) either in the drinking water or as an oral instillation once daily, at ≈ 1 and ≈ 3 mg/kg/day for 45 days after one injection with TGF‐β1 into the tunica albuginea, as an ‘early preventive’ treatment for TGF‐β1‐induced formation of a PD‐like plaque. Other groups received the two doses of vardenafil only in the drinking water, starting with a well‐formed plaque, for 42 days (‘late, therapeutic’ administration). Sections of penile tissue were stained histochemically or immunohistochemically, followed by quantitative image analysis for collagen/smooth muscle and collagen III/I ratios, myofibroblast content (α‐smooth muscle actin), TGF‐β1 expression, and apoptotic index. RESULTS: Preventative treatment with vardenafil at the higher dose (both continuous and once‐daily treatments) reduced the collagen/smooth muscle and collagen III/I ratios, and the numbers of myofibroblasts and TGF‐β1‐positive cells, and selectively increased the apoptotic index in the PD‐like plaque. The lower dose was less effective, When vardenafil was given continuously in the drinking water for 41 days after the PD‐like plaque was formed, there was only a partial reduction of the plaque. CONCLUSIONS: Long‐term oral treatment with vardenafil slows and reverses the early stages of an experimental PD‐like plaque in the rat, and might ameliorate a more advanced plaque.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis
Intengan, H. D., & Schiffrin, E. L. (2001) · Hypertension · doi:10.1161/hy09t1.096249 · Cited by 979
Proposal: Trauma as the Cause of the Peyronie's Lesion
Devine, C. J. J., Somers, K. D., Jordan, G. H., & Schlossberg, S. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65361-8 · Cited by 381
El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R., & Lue, T. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64223-x · Cited by 250
Seftel, A. D. (2004) · Clinical Cardiology · doi:10.1002/clc.4960271305 · Cited by 79
Cited by
Yafi, F. A., Jenkins, L., Albersen, M., Corona, G., Isidori, A. M., Goldfarb, S., Maggi, M., Nelson, C. J., Parish, S., Salonia, A., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.3 · Cited by 853
The Management of Peyronie’s Disease: Evidence-based 2010 Guidelines
Ralph, D., Gonzalez-Cadavid, N., Mirone, V., Perovic, S., Sohn, M., Usta, M., & Levine, L. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01850.x · Cited by 324
Self-citationEAU guidelines on penile curvature
Hatzimouratidis, K., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Salonia, A., Vardi, Y., & Wespes, E. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.040 · Cited by 309
“The rationale for the use of a phosphodiesterase type 5 (PDE5-I) in Peyronie’s disease comes from animal studies showing that they can reduce the collagen/smooth muscle and collagen III/I ratios and increase the apoptotic index in the Peyronie’s diseaselike plaque [26].”
BackgroundThe Management of Peyronie's Disease: Evidence-based 2010 Guidelines
Shindel, A. (2011) · Yearbook of Urology · doi:10.1016/j.yuro.2010.12.007 · Cited by 300
Gonzalez-Cadavid, N. F. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01195.x · Cited by 172
Metadata
- Authors
- FERRINI, M. G., KOVANECZ, I., NOLAZCO, G., RAJFER, J., & GONZALEZ‐CADAVID, N. F.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2006-02-10
- Volume
- 97
- Issue
- 3
- Pages
- 625-633
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2050398117
- Cited by
- 132
- References
- 5
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of long‐term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. https://app.cochat.ai/papers/10.1111/j.1464-410x.2006.05955.x
- The paper
- FERRINI, M. G., KOVANECZ, I., NOLAZCO, G., RAJFER, J., & GONZALEZ‐CADAVID, N. F. (2006). Effects of long‐term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU International. https://doi.org/10.1111/j.1464-410x.2006.05955.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.